ICIs are a form of immunotherapy that has garnered significant attention in recent years for their potential in tumor treatment by targeting and inhibiting immune checkpoints, such as CTLA-4 and PD-1, to activate the immune response (156). The gene discussed is CTLA4; the disease is neoplasm.